日韩精品久久一区二区三区_亚洲色图p_亚洲综合在线最大成人_国产中出在线观看_日韩免费_亚洲综合在线一区

 
 
 

New studies on HIV treatment as prevention

2012-04-26 15:49

 

Get Flash Player

Download

New studies on HIV treatment as prevention

Recent studies have shown that antiretroviral drugs can be used not only to treat HIV, but also to prevent infection in the first place. It's called pre-exposure prophylaxis or PrEP for short. Now, the western US state of California is launching new studies to determine PrEP's effectiveness beyond clinical trials and out in the real world.

Treatment as prevention has been shown to be highly successful in clinical trials. But will it work for people in high risk groups as they go about their daily lives? Will they adhere to the drug regimen even if it's taking only one pill a day?

These are some of the questions the California HIV/AIDS Research Program hopes to answer with three new studies. Mitchell Warren, head of the AIDS advocacy group AVAC, said these are "demonstration studies."

"These are not randomized controlled trials where we're telling people you may get placebo, you may get the active drug. And even if you get the active drug we don't know if it works. These are studies that are going to work with people in communities in California. People who are at risk. [They] are going to be explained that we think this product works based on these clinical trials, but only if you use [it]. And provide it to a small number of people to really better understand the safety and effectiveness in areas outside of clinical trials," he said.

MSM & transgenders

The studies focus on groups where HIV infections are rising rapidly.

Warren said, "All of these activities in California are focused on men who have sex with men and transgender women. And that is entirely understandable and appropriate given the epidemic in the United States. That is the leading area of need. At the same time we really hope as advocates that these demonstration projects in California are the first of many and that many more will look at other populations."

Those taking part in the study are being asked to follow what would appear to be a very simple drug regimen.

"It is a daily dose and it is a combined drug. It's a single pill, but with both active tenofovir and emtricitabine. And it is the same dose that is provided to people who are infected with HIV, who use the same pill for treatment. So the recommendation that was studied in the trial was the same single pill every day," he said.

Daily dose

However, Warren said pre-exposure prophylaxis is only effective if people take the pill. So the studies will also examine why people may skip doses, even if they only have to swallow one pill a day.

"People who took this pill consistently had high levels, an excess of 70 percent reduction of risk. People who didn't take the pill consistently didn't get any benefit at all. There was no added protection," he said.

When antitrovirals first came on the scene in the early and mid-1990s, people had to take dozens of pills a day. They had to take them at very specific times, sometimes with food, sometimes without. They often had very bad side effects, including nausea. There were even conditions called "buffalo hump" and "Crix belly," where body fat would build up behind the neck or on the abdomen. So, while lives were being saved, treatment could make people feel pretty sick.

Warren said it's much different today.

"We also have to remember the incredible scientific advances – from the 80s when getting HIV inevitably meant a very short life and a very painful disease in death – to a period of early antiretroviral therapy where we had drugs that were very difficult to take and very toxic, but they could save your life if you could withstand that – to a point now where people can take one or two pills a day. Much safer, much less toxic. We're in a very different place," he said.

In May, the US Food and Drug Administration will review the PrEP research. It could lead to greater access to prevention as treatment and provide accurate information to healthcare providers, insurance companies and potential users.

placebo: a substance containing no medication and prescribed or given to reinforce a patient's expectation to get well 安慰劑

Related stories:

Better treatment for HIV-positive pregnant women

Much progress, much to do on HIV

New guidelines would help ensure HIV treatment

Hepatitis C kills more Americans than HIV/AIDS

(來源:VOA 編輯:旭燕)

 
中國日報網英語點津版權說明:凡注明來源為“中國日報網英語點津:XXX(署名)”的原創(chuàng)作品,除與中國日報網簽署英語點津內容授權協(xié)議的網站外,其他任何網站或單位未經允許不得非法盜鏈、轉載和使用,違者必究。如需使用,請與010-84883561聯(lián)系;凡本網注明“來源:XXX(非英語點津)”的作品,均轉載自其它媒體,目的在于傳播更多信息,其他媒體如需轉載,請與稿件來源方聯(lián)系,如產生任何問題與本網無關;本網所發(fā)布的歌曲、電影片段,版權歸原作者所有,僅供學習與研究,如果侵權,請?zhí)峁┌鏅嘧C明,以便盡快刪除。

中國日報網雙語新聞

掃描左側二維碼

添加Chinadaily_Mobile
你想看的我們這兒都有!

中國日報雙語手機報

點擊左側圖標查看訂閱方式

中國首份雙語手機報
學英語看資訊一個都不能少!

關注和訂閱

本文相關閱讀
人氣排行
搜熱詞
 
 
精華欄目
 

閱讀

詞匯

視聽

翻譯

口語

合作

 

關于我們 | 聯(lián)系方式 | 招聘信息

Copyright by chinadaily.com.cn. All rights reserved. None of this material may be used for any commercial or public use. Reproduction in whole or in part without permission is prohibited. 版權聲明:本網站所刊登的中國日報網英語點津內容,版權屬中國日報網所有,未經協(xié)議授權,禁止下載使用。 歡迎愿意與本網站合作的單位或個人與我們聯(lián)系。

電話:8610-84883645

傳真:8610-84883500

Email: [email protected]

主站蜘蛛池模板: 国产精品亚洲综合色拍 | 精品黑人一区二区三区 | 日韩欧美综合在线 | 久草久视频 | 国产一级毛片高清视频 | 日本吻胸捏胸激烈床戏视频 | 五月天婷婷综合 | 午夜天堂精品久久久久 | 欧美成人26uuu欧美毛片 | 97色免费视频 | www.久草 | 亚洲六月丁香色婷婷综合久久 | 午夜免费电影院 | 国产精品福利片免费看 | 精品综合在线 | 91精品国产综合久久国产大片 | 亚洲精品一区二区三区不 | 久久成人18免费网站 | 久草视频在线免费播放 | 国产高清在线精品免费 | 偷拍在线观看视频在线观看地址 | 免费一级做a爰片性色毛片 狠狠色欧美亚洲狠狠色www | 日韩精品一| 久久草在线 | 老司机免费福利视频无毒午夜 | 国产三级在线观看 | 亚洲精品视频一区二区三区 | 激情在线网 | 欧美日韩亚洲一区二区三区在线观看 | 噜噜噜噜精品视频在线观看 | 久久亚洲精品国产精品婷婷 | 6080yy精品一区二区三区 | 久久福利青草精品免费 | 婷婷综合久久狠狠色99h | 国产一区久久久 | 毛片啪啪 | 久久88 | 草草草在线观看 | 色综合五月色婷婷开心 | 王的女人印度剧电视剧免费观看32集 | 国产精品福利短视在线播放频 |